Dated disclosed rounds · latest 2023-05-01
Series B
OMass Therapeutics
Drug discovery (native mass spectrometry / membrane protein platform)
VerifiedSeries BOxford
- Companies House
- 10028228
- GLEIF LEI
- Not matched
- Latest evidence
- 2023-05-01
- Evidence snapshot
- 2026-08-25
Exact award notices · latest No exact award match
2026-08-25T03:37:11.076Z
Jun 2026
Signals organise dated evidence; they do not score growth, revenue, creditworthiness or investment performance.
Evidence timeline
3 dated observations
Funding, procurement, registry and identifier records are placed on one chronology. Each row says whether it is a source fact, a record observation or reference metadata; no inferred event is inserted.
RegistryRecord observation Status observed: Active
Snapshot evidence only; this row does not claim the status changed on this date.
FundingSource fact Series B
£75.5M (extended with further £10M from British Patient Capital, 2023) · 7 named investors
RegistryRegistry fact Company incorporated
OMASS THERAPEUTICS LIMITED · company 10028228
Latest disclosed round
Series B
- Date
- 2023-05-01
- Amount
- GBP 75.5m
- Sector
- Biotech & techbio
- Companies House
- 10028228
- ONS region
- South East
Evidence status
Directory ready
- Identity
- Verified
- Match
- High — exact company number and aligned registered name
- Operating status
- active
- Data origins
- Core directory, Growth Network, Live Chris T D1
Capital network
7 linked investors
Lead, participant, lender and other retained roles remain distinct where the source supports them. Every relationship below names its source layer, observation date, match method and publication state.
GVleadNorthpond VenturesleadSanofi VenturesleadBritish Patient CapitalparticipantOxford Science EnterprisesparticipantOxford UniversityparticipantSynconaparticipant
| Investor | Role | Date | Source | Match / state |
|---|---|---|---|---|
| GV | lead | 2023-05-01 | UKTN ↗ · Thebusinessmagazine ↗ | reviewed canonical company and investor alias resolutionsource-linked · published |
| Northpond Ventures | lead | 2023-05-01 | UKTN ↗ · Thebusinessmagazine ↗ | reviewed canonical company and investor alias resolutionsource-linked · published |
| Sanofi Ventures | lead | 2023-05-01 | UKTN ↗ · Thebusinessmagazine ↗ | reviewed canonical company and investor alias resolutionsource-linked · published |
| British Patient Capital | participant | 2023-05-01 | UKTN ↗ · Thebusinessmagazine ↗ | reviewed canonical company and investor alias resolutionsource-linked · published |
| Oxford Science Enterprises | participant | 2023-05-01 | UKTN ↗ · Thebusinessmagazine ↗ · Oxfordscienceenterprises ↗ | reviewed canonical company and investor alias resolutionsource-linked · published |
| Oxford University | participant | 2023-05-01 | UKTN ↗ · Thebusinessmagazine ↗ | reviewed canonical company and investor alias resolutionsource-linked · published |
| Syncona | participant | 2023-05-01 | UKTN ↗ · Thebusinessmagazine ↗ | reviewed canonical company and investor alias resolutionsource-linked · published |
Funding record
1 disclosed round
Open a dated round to move directly between the company, named investors and source publication.
| Date | Stage | Amount | Investors | Named sources |
|---|---|---|---|---|
| 2023-05-01 | Series B | £75.5M (extended with further £10M from British Patient Capital, 2023) | GV · Northpond Ventures · Sanofi Ventures · Syncona · Oxford Science Enterprises · Oxford University · + 1 more linked | UKTN ↗ · Thebusinessmagazine ↗ |
Companies House status and filing snapshot
OMASS THERAPEUTICS LIMITED
Exact company-number match from the public register. The retained status is active. Filing dates and SIC codes are registry context, not a credit or investment-quality assessment.
Registered record
- Status
- Active
- Company type
- Private Limited Company
- Country of origin
- United Kingdom
- Incorporated
- 2016-02-26
- Dissolved
- Not applicable
- Company number
- 10028228
Filing context
- Accounts category
- FULL
- Accounts made up to
- 2025-12-31
- Next accounts due
- 2027-09-30
- Confirmation made up to
- 2026-03-12
- Registry snapshot
- 2026-08-01
- Live check
- 2026-08-25T03:37:11.076Z
Former registered names: OMASS TECHNOLOGIES LIMITED
72110Research and experimental development on biotechnology
CompanyBeacon statutory projection
OMASS THERAPEUTICS LIMITED
UK Capital Intelligence owns the capital view on this page. CompanyBeacon owns the exact legal-entity, filing, control and public-record timeline for company number 10028228.
Latest retained status
active
- Checked
- 2026-08-25T03:37:11.076Z
- Recorded change
- No change timestamp retained
- Previous status
- active
- Fund associations
- 3 dated CompanyBeacon memberships
Boundary
Verify the legal record
Fund association does not prove a current holding. Status change is a review signal, not investment performance or wrongdoing. Ownership and control are not copied into this public UKCI package.
Open CompanyBeacon record ↗Traceability
Source trail
Funding and investor claims retain named public-source links. This is a dated research snapshot, not a live cap table.